NASDAQ:GILD - Gilead Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$62.88 -0.16 (-0.25 %)
(As of 04/24/2019 03:55 PM ET)
Previous Close$63.04
Today's Range$62.22 - $63.25
52-Week Range$60.32 - $79.61
Volume411,489 shs
Average Volume7.47 million shs
Market Capitalization$80.20 billion
P/E Ratio10.22
Dividend Yield4.07%
Beta1.16
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GILD
CUSIP37555810
Phone650-574-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.13 billion
Cash Flow$7.3201 per share
Book Value$16.65 per share

Profitability

Net Income$5.46 billion

Miscellaneous

Employees11,000
Outstanding Shares1,275,510,000
Market Cap$80.20 billion
Next Earnings Date5/2/2019 (Confirmed)
OptionableOptionable

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Monday, February 4th. Stockholders of record on Friday, March 15th will be paid a dividend of $0.63 per share on Thursday, March 28th. This represents a $2.52 annualized dividend and a dividend yield of 4.01%. The ex-dividend date of this dividend is Thursday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.57. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) announced its earnings results on Monday, February, 4th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.70 by $0.26. The biopharmaceutical company earned $5.80 billion during the quarter, compared to analyst estimates of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The business's revenue was down 2.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.78 EPS. View Gilead Sciences' Earnings History.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Gilead Sciences.

How can I listen to Gilead Sciences' earnings call?

Gilead Sciences will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

What price target have analysts set for GILD?

19 Wall Street analysts have issued 1 year target prices for Gilead Sciences' shares. Their predictions range from $68.00 to $95.00. On average, they expect Gilead Sciences' stock price to reach $81.9375 in the next twelve months. This suggests a possible upside of 30.2% from the stock's current price. View Analyst Price Targets for Gilead Sciences.

What is the consensus analysts' recommendation for Gilead Sciences?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 7 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gilead Sciences.

What are Wall Street analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:
  • 1. According to Zacks Investment Research, "Gilead’s HIV franchise maintains momentum, driven by continued uptake of Genvoya and Odefsey, and the rapid adoption of Biktarvy. However, the company’s HCV franchise continues to witness a slowdown across key markets, including the United States and Europe, as a result of competition and pricing pressure. Consequently, Gilead shifted focus to its HIV franchise, and newer avenues like CAR-T therapy and NASH. However, the company suffered a setback with the failure of a late-stage study on selonsertib in patients with compensated cirrhosis (F4) due to NASH. Shares have underperformed the industry in the past six months." (4/23/2019)
  • 2. Maxim Group analysts commented, "Gilead and Galapagos NV (GLPG – NR) reported positive data from two P3 studies of JAK1 inhibitor filgotinib in treating rheumatoid arthritis (RA); FINCH-1 and FINCH-3. Recall the FINCH-2 trial read-out in 3Q18. All three trials met their primary endpoints as well as multiple secondary endpoints." (3/29/2019)
  • 3. Mizuho analysts commented, "We spoke to GILD. The company was able to confirm the title and time, and it noted that yes, this this is the pivotal DISCOVER trial, but couldn’t say exactly what data we will get. The company also confirmed that it’s a late-breaker and also an oral presentation. Clinicaltrials.gov still shows an active" status, but GILD noted to us that in general (not necessarily specific to this particular Descovy entry) clincaltrials.gov results can be presented at a lag. We note that oral presentations typically need to be informative, can’t just be baseline data, etc … our best guess is we’re getting both efficacy and safety data." (2/26/2019)
  • 4. Cantor Fitzgerald analysts commented, ": We are increasing our price target to $88 from $87 and reiterating our Overweight rating. Gilead beat top and bottom line consensus expectations as the Biktarvy launch remains strong in HIV. Our price target is higher by $1/share given revenue trends were slightly more robust than we projected. The company also increased its product revenue guidance to $20.8-21.3B from $20-21B. Product revenues were $5.45B and EPS were $1.84/share. Biktarvy beat expectations by ~$50M, as it reported revenues of $375M. GILD has also benefited from a generic Letairis not entering the market, and it doesn’t expect an entrant in 2018. We have updated our estimates for the quarter." (10/26/2018)

Has Gilead Sciences been receiving favorable news coverage?

Media headlines about GILD stock have been trending somewhat positive this week, according to InfoTrie. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Gilead Sciences earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future.

Who are some of Gilead Sciences' key competitors?

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include Celgene (CELG), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Walt Disney (DIS), Intel (INTC), NVIDIA (NVDA), Bank of America (BAC), AT&T (T) and Starbucks (SBUX).

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:
  • Daniel O'Day, Chairman & Chief Executive Officer
  • Robin L. Washington, CFO, Principal Accounting Officer & Executive VP
  • John G. McHutchison, Chief Scientific Officer
  • Brett A. Pletcher, Secretary, Chief Compliance Officer & Executive VP
  • William A. Lee, Executive Vice President-Research

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include First Manhattan Co. (0.16%), PGGM Investments (0.13%), Confluence Investment Management LLC (0.09%), Mondrian Investment Partners LTD (0.09%), Retirement Systems of Alabama (0.08%) and Factory Mutual Insurance Co. (0.07%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, Richard James Whitley and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Which major investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including Avalon Advisors LLC, First Manhattan Co., Ferguson Wellman Capital Management Inc., LaFleur & Godfrey LLC, Busey Wealth Management, DNB Asset Management AS, First Hawaiian Bank and First National Bank of Mount Dora Trust Investment Services. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, John C Martin, John Francis Cogan and Richard James Whitley. View Insider Buying and Selling for Gilead Sciences.

Which major investors are buying Gilead Sciences stock?

GILD stock was bought by a variety of institutional investors in the last quarter, including Factory Mutual Insurance Co., Pacer Advisors Inc., Mondrian Investment Partners LTD, Manning & Napier Group LLC, Exane Derivatives, PGGM Investments, Mercer Global Advisors Inc. ADV and Underhill Investment Management LLC. View Insider Buying and Selling for Gilead Sciences.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $62.91.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $80.24 billion and generates $22.13 billion in revenue each year. The biopharmaceutical company earns $5.46 billion in net income (profit) each year or $6.15 on an earnings per share basis. Gilead Sciences employs 11,000 workers across the globe.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is http://www.gilead.com.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]gilead.com.


MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  2,030 (Vote Outperform)
Underperform Votes:  916 (Vote Underperform)
Total Votes:  2,946
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel